GI-19007, a Novel Saccharomyces cerevisiae-Based Therapeutic Vaccine against Tuberculosis.

about

GI-19007, a Novel Saccharomyces cerevisiae-Based Therapeutic Vaccine against Tuberculosis.

Item

http://www.wikidata.org/entity/Q46310148

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

GI-19007, a Novel Saccharomyce ...... Vaccine against Tuberculosis.

@en

GI-19007, a Novel Saccharomyce ...... Vaccine against Tuberculosis.

@nl

type

Item

label

GI-19007, a Novel Saccharomyce ...... Vaccine against Tuberculosis.

@en

GI-19007, a Novel Saccharomyce ...... Vaccine against Tuberculosis.

@nl

prefLabel

GI-19007, a Novel Saccharomyce ...... Vaccine against Tuberculosis.

@en

GI-19007, a Novel Saccharomyce ...... Vaccine against Tuberculosis.

@nl

P1476

GI-19007, a Novel Saccharomyce ...... Vaccine against Tuberculosis.

@en

P2093

Crystal A Shanley

http://www.w3.org/2001/XMLSchema#string

Donald Bellgrau

http://www.w3.org/2001/XMLSchema#string

Ian M Orme

http://www.w3.org/2001/XMLSchema#string

Marcela Henao-Tamayo

http://www.w3.org/2001/XMLSchema#string

Synthia Furney

http://www.w3.org/2001/XMLSchema#string

Thomas H King

http://www.w3.org/2001/XMLSchema#string

Timothy Rodell

http://www.w3.org/2001/XMLSchema#string

Zhimin Guo

http://www.w3.org/2001/XMLSchema#string

P2860

Glucopyranosyl lipid A adjuvant significantly enhances HIV specific T and B cell responses elicited by a DNA-MVA-protein vaccine regimen

Vaccine development for tuberculosis: current progress

Tuberculosis vaccine types and timings

A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations

A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines.

CD4+ and CD8+ T cell- and IL-17-mediated protection against Entamoeba histolytica induced by a recombinant vaccine.

Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140.

In a murine tuberculosis model, the absence of homeostatic chemokines delays granuloma formation and protective immunity.

Phenotypic definition of effector and memory T-lymphocyte subsets in mice chronically infected with Mycobacterium tuberculosis.

A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance.

P31

scholarly article

P356

10.1128/CVI.00245-17

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29046306

http://www.w3.org/2001/XMLSchema#string

P921

Saccharomyces cerevisiae

P932

5717186

http://www.w3.org/2001/XMLSchema#string